Fairmount's 19.99% stake and board representation rights give it significant influence over Mentari's strategic direction, particularly regarding migraine prevention therapies. Monitor for any future proposals from Fairmount regarding operational changes, capital allocation, or strategic alternatives.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $18.60entry
- T+1 · 20h ago +6.83%α +8.74% · $19.87
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fairmount Funds Management LLC filed a Schedule 13D disclosing beneficial ownership of 19.99% of Mentari Therapeutics (formerly InMed Pharmaceuticals) common stock, acquired through a reverse merger and PIPE financing. The stake was obtained as part of the merger consideration and a $490M pre-closing financing, with Fairmount holding 10,555,507 shares and additional convertible preferred stock and pre-funded warrants subject to ownership limitations.
Key Financial Metrics
Key Facts
- Fairmount Funds Management LLC and affiliated entities own 19.99% of Mentari Therapeutics common stock as of November 6, 2026
- The stake consists of 10,555,507 shares of common stock directly held by Fairmount Healthcare Fund II L.P.
- Fairmount also holds 4,013 shares of Series A Non-Voting Convertible Preferred Stock convertible into 4,013,000 common shares and 1,468,222 pre-funded warrants, both subject to 19.99% beneficial ownership limitations
- The aggregate purchase price for the common stock and pre-funded warrants was $119,999,263, plus $200,000 for the Series A Preferred Stock
- The stake was acquired through the November 6, 2026 reverse merger of InMed Pharmaceuticals with Mentari Therapeutics and a concurrent $490M pre-closing financing
- Fairmount has the right to elect two directors as long as at least 30% of Series A Preferred Stock remains outstanding
- Lock-up agreements restrict sale of shares for 180 days after the merger closing
Financial Impact
$120.2 million total investment for 19.99% stake (common + preferred + warrants)
Risk Factors
- Fairmount's beneficial ownership limitations (19.99%) may cap future conversion of preferred stock and warrants, limiting potential dilution
- Lock-up agreements expire 180 days post-merger, potentially leading to selling pressure
- The filing states no present plans for actions under Item 4, but Fairmount may develop plans in the future
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D Filing (Primary) | 0001193125-26-458677 |
| Document: 0001193125-26-458677-index.html | 0001193125-26-458677 |
| Document: 0001193125-26-458677.txt | 0001193125-26-458677 |
Track record
10 reports on MTRI
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $17.90 Now $19.87 −11.01% settles Dec 15
- Nov 16, 2026today 8-K Neutral 6/10 Entry $18.60 Now $19.87 +6.83% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $19.02 Now $19.87 +4.47% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $15.75 Now $19.87 +26.16% settles Dec 15
- Nov 12, 20264d ago SC 13D Neutral 5/10 Viewing Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 10, 20266d ago 8-K Mixed 7/10 Entry $15.61 Now $19.87 +27.30% settles Dec 10
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers